Alzheimer's Association Disappointed by United Kingdom's Decision to Deny Coverage of Donanemab
October 24, 2024
October 24, 2024
CHICAGO, Illinois, Oct. 24 -- The Alzheimer's Association issued the following news release on Oct. 23, 2024:
The Alzheimer's Association is disappointed that once again the United Kingdom has decided to block access to a disease modifying Alzheimer's treatment. Today, the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) approved Kisunla(R) (donanemab) for the treatment of Alzheimer's disease -- an important step toward treatment choice in the U.K. However . . .
The Alzheimer's Association is disappointed that once again the United Kingdom has decided to block access to a disease modifying Alzheimer's treatment. Today, the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) approved Kisunla(R) (donanemab) for the treatment of Alzheimer's disease -- an important step toward treatment choice in the U.K. However . . .